In a clinical trial on 47 colorectal cancer patients, several immune parameters such as IL‐1, IL‐6, IFN‐γ, CD3 and CD4 were altered after 12 weeks of oral administration of G. lucidum, suggesting that it may be helpful in modulating tumour immunity.45 The gene discussed is CD4; the disease is colorectal cancer.